SCHEMBL2433879

SCHEMBL2433879

COc1ccc(COc2nc(I)ccc2OCc2ccccc2)cc1

nearest known ligand 0.53

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ABCB1 P08183 2/20 0.53
ALDH1A1 P00352 1/20 0.49
LMNA P02545 1/20 0.49
HTT P42858 1/20 0.49
NPSR1 Q6W5P4 1/20 0.49
APP P05067 3/20 0.49
CNR1 P21554 2/20 0.48
CNR2 P34972 2/20 0.48
NPC1 O15118 1/20 0.48
RAB9A P51151 1/20 0.48
LTA4H P09960 1/20 0.46
CSF1R P07333 1/20 0.46
MEN1 O00255 1/20 0.45
BCHE P06276 1/20 0.45
KMT2A Q03164 1/20 0.45
HRH4 Q9H3N8 1/20 0.44
MAOB P27338 1/20 0.44
CTSL P07711 1/20 0.44
CTSB P07858 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2413783 0.88 APP (0.54) ABCB1APPCNR1CNR2NPC1
SCHEMBL2414177 0.88 APP (0.54) APPCNR1CNR2NPC1RAB9A
SCHEMBL15577719 0.88 L3MBTL1 (0.47) ALDH1A1LMNAHTTAPPNPC1
SCHEMBL23167115 0.87 APP (0.50) ABCB1APPCNR1CNR2NPC1
SCHEMBL23121541 0.87 APP (0.49) ABCB1ALDH1A1LMNAHTTNPSR1
SCHEMBL2409162 0.85 APP (0.48) LMNAHTTAPPCNR1CNR2
SCHEMBL2416615 0.82 APP (0.48) ABCB1ALDH1A1LMNAAPPCNR1
SCHEMBL15577512 0.82 ALDH1A1 (0.54) ABCB1ALDH1A1LMNAHTTNPSR1
SCHEMBL2418124 0.81 APP (0.47) APPCNR1CNR2NPC1RAB9A
SCHEMBL14478707 0.80 APP (0.54) ALDH1A1LMNAHTTNPSR1APP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9309199-B2 Inhibitors of catechol O-methyl transferase and their use in the treatment of psychotic disorders MERCK SHARP & DOHME CORP. (US) 2016-04-12 US disclosed
US-9309199-B2 Inhibitors of catechol O-methyl transferase and their use in the treatment of psychotic disorders MERCK SHARP & DOHME CORP. (US) 2016-04-12 US disclosed
US-9309199-B2 Inhibitors of catechol O-methyl transferase and their use in the treatment of psychotic disorders MERCK SHARP & DOHME CORP. (US) 2016-04-12 US disclosed
EP-2542077-A1 INHIBITORS OF CATECHOL O-METHYL TRANSFERASE AND THEIR USE IN THE TREATMENT OF PSYCHOTIC DISORDERS Merck Sharp & Dohme Corp. (US) 2013-01-09 EP disclosed
US-20130005744-A1 INHIBITORS OF CATECHOL O-METHYL TRANSFERASE AND THEIR USE IN THE TREATMENT OF PSYCHOTIC DISORDERS MERCK SHARP & DOHME LLC 2013-01-03 US disclosed
US-20130005744-A1 INHIBITORS OF CATECHOL O-METHYL TRANSFERASE AND THEIR USE IN THE TREATMENT OF PSYCHOTIC DISORDERS MERCK SHARP & DOHME LLC 2013-01-03 US disclosed
US-20130005744-A1 INHIBITORS OF CATECHOL O-METHYL TRANSFERASE AND THEIR USE IN THE TREATMENT OF PSYCHOTIC DISORDERS MERCK SHARP & DOHME LLC 2013-01-03 US disclosed
WO-2011109261-A1 INHIBITORS OF CATECHOL O-METHYL TRANSFERASE AND THEIR USE IN THE TREATMENT OF PSYCHOTIC DISORDERS MERCK SHARP & DOHME CORP. (US) 2011-09-09 WO disclosed
WO-2011109261-A1 INHIBITORS OF CATECHOL O-METHYL TRANSFERASE AND THEIR USE IN THE TREATMENT OF PSYCHOTIC DISORDERS MERCK SHARP & DOHME CORP. (US) 2011-09-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130005744-A1 INHIBITORS OF CATECHOL O-METHYL TRANSFERASE AND THEIR USE IN THE TREATMENT OF PSYCHOTIC DISORDERS COMT, PNMT, TPMT ABCB1 164/4885ALDH1A1 186/4885LMNA 3949/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.